Diamond Therapeutics has announced that the first patient has been enrolled in its FDA-authorised UAB-Diamond trial evaluating low-dose psilocybin in patients with demoralization.
A new initiative, the PsychedeliCare Initiative, will launch in 2024 to bring citizens together to educate about psychedelics, call for the reshaping of drug policy and...
Awakn Life Sciences recently announced the completion of its feasibility study for its proprietary formulation of MDMA using Catalent’s Zydis® orally disintegrating tablet (ODT) technology.
The placebo effect is the mysterious power our minds have to make us feel better, even when we are taking just a sugar pill instead of...
Health Canada has given Filament Health authorisation to carry out a Phase 2 clinical trial investigating PEX010 – the company’s botanical psilocybin drug candidate – for...
MIND Foundation’s INSIGHT Conference took place from August 31 to September 3 in Berlin, exploring the latest frontiers in psychedelic medicines – from clinical developments to...
New research has revealed that MDMA and methamphetamine deepen personal connections following guided conversations, and suggests different mechanisms for how these drugs produce feelings of closeness.
A team of researchers has analysed the experience of people with Obsessive-Compulsive Disorder (OCD) who have taken psychedelics, finding 30% experienced relief from their symptoms.
Results from a new analysis have revealed an improvement in mental health and cognition for Special Operations Forces veterans following a combination of psychedelic treatments.
Results from a major clinical trial have shown that esketamine outperforms one of the standard treatments for treatment-resistant major depression disorder (MDD).